H.C. Wainwright Upgrades Cardiff Oncology After Nerviano Settlement Clears Onvansertib Path
The catalyst: an out-of-court deal that keeps exclusive rights to onvansertib. Cash remains tight.
/ 185 items
#XY Analyst Up/Down↓
Berenberg Sees 25% Upside in Eli Lilly as Obesity Drugs Keep Winning
Berenberg upgraded Eli Lilly from Hold to Buy and lifted its target to $1,400, citing obesity-drug leadership and a likely 2026 guidance beat.
Cellectis Drops Blood-Cancer CAR-Ts; Citizens Cuts Rating
Citizens cut Cellectis to Market Perform after it scrapped allogeneic CAR-T programs and pivoted to in-vivo gene editing for high triglycerides and cholesterol. Catalysts now 2027–28.
B. Riley Turns Bullish on Capricor Before November Deramiocel Decision
B. Riley upgrades Capricor to Buy from Neutral and lifts its target to $21 from $5 ahead of the Nov. 22, 2026 deramiocel FDA date.
Auvelity’s Early Alzheimer’s Agitation Launch Draws Bullish Analyst Notes
Mizuho, Needham and Guggenheim cite 32–34% script growth and robust 65+ uptake as Auvelity’s Alzheimer’s agitation launch gets off to a strong start.
JPMorgan Puts $135 Target on Dianthus After Starting Coverage
Lead drug claseprubart (also known as DNTH103) plus $1.2B cash into 2030.